Bioscience Animal Health PCL
SET:BIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (1.3), the stock would be worth ฿2.45 (20% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.1 | ฿2.04 |
0%
|
| 3-Year Average | 1.3 | ฿2.45 |
+20%
|
| 5-Year Average | 1.3 | ฿2.45 |
+20%
|
| Industry Average | 17 | ฿31.78 |
+1 458%
|
| Country Average | 12.6 | ฿23.62 |
+1 058%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| TH |
B
|
Bioscience Animal Health PCL
SET:BIS
|
640.6m THB | 1.1 | 16.6 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
101.9B USD | 10.7 | 23.5 | |
| US |
|
Cencora Inc
NYSE:COR
|
60.3B USD | 18.4 | 37.2 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.2B USD | 18 | 36.4 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.8B USD | 9.7 | 28.7 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
31.9B AUD | 61.6 | 34.8 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.6B CNY | 19.3 | 10.8 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
61.7B CNY | 162.5 | 21.2 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.9B USD | 22.8 | 22.5 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -285 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
60B HKD | 0.5 | 7.2 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.8 |
| Median | 12.6 |
| 70th Percentile | 17.3 |
| Max | 6 871.7 |
Other Multiples
Bioscience Animal Health PCL
Glance View
Bioscience Animal Health Public Co. Ltd. engages in manufacturing, importing, and distribution of medical supplies, tools, equipment, and products for livestock and pets. The company is headquartered in Pak Kret, Nonthaburi. The company went IPO on 2022-05-05. The firm is an importer and distributor of medical supplies, tools, equipment and products for livestock and pets. The company focuses on selecting products by specialist veterinarians to improve animal health. The firm's products include antibiotic, additive, BiSMiX B-Series, BiSMiX SD Series, injection, mold inhibitor, water-soluble products, vaccine and certificate bioscience. The antibiotic includes Omnicide FG II 1 Lit, Green Bioxide 20Liter, Salinopharm, Cevazuril, and Porcillin. Its additive pHorce, orego-stim-powder, Optiphos, Moldgard, Mastercube and Lianol solapro. The injection consists of Zuprevo, Nuflor, Ceva and Enzaprost. The water-soluble products consist of Tilmosin AC, Surmox col and Coliscour. The firm's subsidiaries include Feed and Ingredients Technological Hub Co., Ltd., Special Ingredient Services Co., Ltd., and others.
